Kyowa Kirin has been granted a patent for a monoclonal antibody that binds to human CCR1, inhibiting its activation by CCL15. The patent covers specific antibody sequences and their fragments, along with therapeutic and diagnostic applications for CCR1-related diseases. GlobalData’s report on Kyowa Kirin gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kyowa Kirin Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kyowa Kirin, was a key innovation area identified from patents. Kyowa Kirin's grant share as of February 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.

Monoclonal antibody inhibiting ccr1 activation by ccl15

Source: United States Patent and Trademark Office (USPTO). Credit: Kyowa Kirin Co Ltd

A recently granted patent (Publication Number: US11912775B2) discloses a monoclonal antibody or antibody fragment that binds to a specific region of the human CC chemokine receptor 1 (CCR1) and inhibits its activation by a human CC chemokine ligand 15 (CCL15). The patent lists various specific antibodies with defined amino acid sequences that exhibit this inhibitory activity. Additionally, the antibody is capable of inhibiting the migration of human CCR1-expressing cells induced by CCL15, further highlighting its potential therapeutic applications in modulating immune responses.

Moreover, the patent covers genetically recombinant antibodies, antibody fragments, and derivatives of the antibody that can be conjugated with various compounds such as radioisotopes, low molecular drugs, high molecular drugs, proteins, or other antibody drugs. These derivatives expand the potential applications of the monoclonal antibody in targeted therapy for various conditions. The patent also includes methods for producing the monoclonal antibody, hybridomas that produce the antibody, nucleic acids encoding the antibody, transformant cells containing the nucleic acids, and methods for producing antibody fragments. Overall, the patent provides a detailed description of the monoclonal antibody's characteristics, potential applications, and methods for production, offering valuable insights for researchers and developers in the field of immunotherapy.

To know more about GlobalData’s detailed insights on Kyowa Kirin, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies